Cognitive Fusion Prostate Biopsy With Biparametric Magnetic Resonance in the Detection of Prostate Cancer

Trial Title: Cognitive Fusion Prostate Biopsy With Biparametric Magnetic Resonance in the Detection of Prostate Cancer

NCT ID: NCT05818631

Condition: Prostate Cancer
Prostate Cancer Diagnosis

Conditions: Official terms:
Prostatic Neoplasms

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Diagnostic Test
Intervention name: fusion cognitive prostate biopsy
Description: A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
Arm group label: MRI +

Other name: directed prostate biopsy

Summary: The goal of this prospective observational study is to evaluate the diagnostic precision of the Biparametric Magnetic Resonance Imaging (bpMRI) in the detection of clinically significant prostate cancer (PCa) in patients with biochemical suspicion of prostate cancer with PSA (Prostate Specific Antigen) > 4 ng/mL and a normal digital rectal examination and without a biopsy previous to the MRI. Secondary aims are: - Determine the validity as a diagnostic test of the first directed transrectal prostatic biopsy (cognitive fusion) versus systematic biopsy of 12 cylinders in patients with suspicious lesions in the bpMRI. - Develop a predictive nomogram that permits the reduction of the number of prostatic biopsies performed to patients with a low suspicion of prostate cancer in the bpMRI.

Detailed description: In Spain, PCa is the most common cancer independently from gender and the third cause of death in man, below lung and colorectal cancer. Incidence and mortality increase progressively as age increases, hence, due to an older population, this is an outstanding sociosanitary concern. PCa generally is asymptomatic, diagnosis is based on prostate biopsy in man with an elevated Prostate Specific Antigen (PSA) in blood test and/or a pathologic digital rectal examination. Multiparametric Magnetic Resonance Imaging (MRImp) plays an important role in the diagnosis. It allows the visualization of the tumor, it values its agresitivity with a scale named "Prostate Imaging-Reporting and Data System" (PI-RADS v2 scale), and permits a directed biopsy to the suspicious lesion. This tecnique is expensive and very uncomfortable for the patient due its duration (40 minutes) and because it uses intravenous (iv) contrast. Due to these reasons, it is difficult to assume by the sanitary system to perform this technique to every patient with PCa suspicion. Biparametric MRI emerges as an alternative with a new protocol, performed with less image sequences (T2 and diffusion), cheaper, lasting less (just 15 minutes), and without the administration of iv contrast. Thus, this technique is more assumable by a public sanitary system.

Criteria for eligibility:

Study pop:
The study will be performed in the 17th department of the Valencian Community (San Juan de Alicante's Department). Main patients are those that visit the consultation room in the Urological department of the Hospital Universitario San Juan de Alicante.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Male patients between 18 and 80 years - BpMRI performed in a 3 months period before the prostatic biopsy - First transrectal prostatic biopsy - PSA > 4 ng/mL and < 20 ng/mL - Patients acceptance to participate in the study signing a written specific informed consent Exclusion Criteria: - Not having all the inclusion criteria described - Suspicious digital rectal examination of prostate cancer - Previous urinary tract infection in the last six months, acute urinary retention or being a chronic carrier of bladder catheter - Previous prostatic surgery in any of its variants - Concomitant treatment with Luteinizing hormone-releasing hormone (LHRH) analogue, antiandrogens or 5-alfa-reductase inhibitors

Gender: Male

Minimum age: 18 Years

Maximum age: 80 Years

Healthy volunteers: No

Locations:

Facility:
Name: Universidad Miguel Hernández de Elche

Address:
City: Alicante
Zip: 03550
Country: Spain

Status: Recruiting

Contact:
Last name: BARAA NAKDALI KASSAB

Phone: 663292199
Email: baranakdali@hotmail.com

Start date: March 1, 2021

Completion date: February 2024

Lead sponsor:
Agency: José Joaquín Mira
Agency class: Other

Source: Universidad Miguel Hernandez de Elche

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05818631